Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:INAB

IN8bio Q1 2026 Earnings Report

IN8bio logo
$1.57 -0.03 (-2.13%)
As of 12:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

IN8bio EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.33
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q1 2026
Date
5/7/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

IN8bio's Q1 2026 Press ReleasePress Release
(8-K)
IN8bio's Q1 2026 Quarterly reportQuarterly report
(10-Q)

IN8bio Earnings Headlines

IN8bio, Inc: IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
 |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68436859-in8bio-inc-in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights-399.htm
IN8bio Reports Q1 2026 Results and Shareholder Votes
May 7 at 7:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/in8bio-reports-q1-2026-results-and-shareholder-votes?utm_source=marketbeat.com&utm_medium=referral
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 8 at 1:00 AM  |  Profits Run (Ad)
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 7 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290667/0/en/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
May 6 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288735/0/en/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-r-d-day-and-medical-conferences.html
IN8bio (INAB) Expected to Announce Earnings on Wednesday
May 5 at 4:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759374
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB) is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

View IN8bio Profile
Earnings Tools